ADVFN Logo ADVFN
시장 데이터
뉴스
도구
시장
팔로우

Hot Features

피드 팔로우

Follow Feed 커뮤니티에서 거래자 및 투자자와 연결하세요.

실시간 옵션 플로우

포괄적인 옵션 데이터를 탐색하고 옵션 흐름으로 고급 필터를 사용하세요.

모니터

터미널 모니터로 주식 및 자산 관심 목록을 구성하고 모니터링하세요.
로그인 Premium Icon프리미엄 Help Menu
S&P 500
5,099.96
1.02%
US Tech 100
17,244.80
1.57%
다우존스 지수
38,239.66
0.40%
Bitcoin
63,082.61
-1.03%
Registration Strip Icon for discussion 같은 생각을 가진 투자자들과 토론할 수 있는 활발한 포럼에서 상호 작용하려면 등록하세요.
등록
  1. 홈
  2. 인베스팅
  3. 주식
  4. 미국
  5. NASDAQ
  6. Arcutis Biotherapeutics Inc (ARQT)

  7. Arcutis Biotherapeutics Inc (ARQT) 뉴스

ARQT Arcutis Biotherapeutics Inc

8.31
-0.28 (-3.26%)
27 4월(4) 2024 - 마감
15분 지연
기업명 주식 심볼 시장 주식 타입
Arcutis Biotherapeutics Inc ARQT 나스닥 보통주
  가격 변동 가격 변동 % 주식 가격 최근 거래 시간
Upgrade Icon
-0.28 -3.26% 8.31 08:46:45
개장가 저가 고가 종가 전일 종가
8.59 8.36 8.85 8.47 8.59
시세 정보 더보기 »

최근 뉴스

일자 시간 출처 제목
10/04/202421:00GLOBEArcutis Appoints David Topper as Chief Financial Officer
06/04/202405:00GLOBEArcutis Biotherapeutics Reports Inducement Grants Under..
01/04/202420:00GLOBESol-Gel’s Collaboration Partner First-to-File ANDA Drug..
28/03/202421:00GLOBEArcutis to Present at the 23rd Annual Needham Virtual..
11/03/202421:00GLOBEArcutis Promotes Todd Tucker to Chief Human Resources..
11/03/202405:00GLOBEArcutis Presents Late-Breaking Data From INTEGUMENT-PED..
10/03/202406:00GLOBENew Research Reveals Genomic Profile of Seborrheic..
07/03/202407:14EDGAR2Form 4 - Statement of changes in beneficial ownership of..
07/03/202407:09EDGAR2Form 4 - Statement of changes in beneficial ownership of..
07/03/202407:08EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06/03/202406:00GLOBEArcutis Biotherapeutics Reports Inducement Grants Under..
05/03/202407:47EDGAR2Form 144 - Report of proposed sale of securities
05/03/202407:42EDGAR2Form 144 - Report of proposed sale of securities
05/03/202407:40EDGAR2Form 144 - Report of proposed sale of securities
05/03/202406:10EDGAR2Form 8-K - Current report
05/03/202406:00GLOBEArcutis Announces Closing of Public Offering of Common Stock..
04/03/202422:00GLOBEArcutis Announces Acceptance of Late Breaking Abstract in..
02/03/202406:11EDGAR2Form 4 - Statement of changes in beneficial ownership of..
02/03/202406:06EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
01/03/202407:00GLOBEArcutis to Present at the TD Cowen 44th Annual Health Care..
29/02/202413:30GLOBEArcutis Announces Pricing of $150 Million Public Offering
29/02/202406:54EDGAR2Form 144 - Report of proposed sale of securities
29/02/202406:21EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
29/02/202406:10EDGAR2Form 8-K - Current report
29/02/202406:10GLOBEArcutis Announces Proposed Public Offering
29/02/202406:00GLOBEArcutis and Sato Announce Strategic Collaboration and..
28/02/202406:34EDGAR2Form S-8 - Securities to be offered to employees in employee..
27/02/202421:48EDGAR2Form 10-K - Annual report [Section 13 and 15(d), not S-K..
27/02/202421:44EDGAR2Form 8-K - Current report
27/02/202419:50GLOBEArcutis Announces Fourth Quarter and Full Year 2023..
16/02/202422:00GLOBEArcutis to Report Fourth Quarter and Full Year 2023..
16/02/202408:47EDGAR2Form 4 - Statement of changes in beneficial ownership of..
16/02/202408:32EDGAR2Form 4 - Statement of changes in beneficial ownership of..
16/02/202408:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
16/02/202406:20EDGAR2Form 8-K - Current report
16/02/202406:19EDGAR2Form SC TO-I/A - Tender offer statement by Issuer: [Amend]
13/02/202423:26EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
09/02/202414:15EDGAR2Form EFFECT - Notice of Effectiveness
09/02/202406:31EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
07/02/202406:00GLOBEArcutis Biotherapeutics Reports Inducement Grants Under..
01/02/202407:22EDGAR2Form S-3 - Registration statement under Securities Act of..
31/01/202422:00GLOBEArcutis to Present at the Guggenheim Healthcare Talks – 6th..
29/01/202422:00GLOBEJournal of the American Academy of Dermatology Publishes..
25/01/202406:02EDGAR2Form SC TO-I/A - Tender offer statement by Issuer: [Amend]
22/01/202422:00GLOBEZORYVE® (roflumilast) Topical Foam, 0.3%, for the Treatment..
18/01/202406:34EDGAR2Form 4 - Statement of changes in beneficial ownership of..
18/01/202406:32EDGAR2Form 4 - Statement of changes in beneficial ownership of..
18/01/202406:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
18/01/202406:28EDGAR2Form 4 - Statement of changes in beneficial ownership of..
14/01/202418:00GLOBEMajority of Individuals with Atopic Dermatitis Improved with..

최근 히스토리

NASDAQ
ARQT
Arcutis Biotherapeutics
Delayed Upgrade Clock
ADVFN Logo

대한변국
회사 소개
사업
Popular
앱 받기

도움 및 지원받기: kr-support@advfn.com

ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관

© 2024 ADVFN PLC - 모든 권리 보유